Viridian debuts on market with FDA greenlight for thyroid eye disease drug

FDA Approves Viridian's Lumvoa for Broad Thyroid Eye Disease Indication

Viridian Therapeutics has received FDA approval for its intravenous therapy veligrotug-vvze, branded as Lumvoa, for the treatment of thyroid eye disease (TED) regardless of disease activity. This approval marks Viridian's first commercial product and is supported by robust data from the Phase 3 THRIVE program. Lumvoa is notable for being the first FDA-approved TED treatment with labeling that includes data for both active and chronic forms of the illness. The company announced immediate availability, positioning Lumvoa to compete with existing therapies like Amgen's Tepezza.

• Lumvoa's FDA approval is significant for its broad label, being the first treatment for thyroid eye disease with data included for both active and chronic forms of the illness. This comprehensive indication, as noted by Truist Securities, provides a strong foundation for its market launch and differentiates it from competitors in the TED therapeutic landscape.
• The approval is backed by compelling efficacy data from the Phase 3 THRIVE program. Specifically, the THRIVE-2 study demonstrated a statistically significant 48% placebo-adjusted proptosis responder rate. Furthermore, long-term data from the THRIVE study showed that 70% of patients who achieved proptosis response at 15 weeks maintained this effect through 52 weeks, highlighting Lumvoa's rapid and durable treatment profile.
• Viridian Therapeutics is initiating an immediate market launch for Lumvoa, with the drug available for prescription shortly after its Friday evening approval. Lumvoa enters a competitive market, with Amgen's Tepezza being a key established therapy, which reported sales of $457 million in Q4 2025 and $490 million in Q1 2026. Amgen is also developing a subcutaneous formulation of Tepezza to enhance its market position.

Addressing Active and Chronic TED: Lumvoa's Unique Label

Thyroid eye disease (TED) continues to present significant clinical and strategic challenges despite the paradigm shift brought by teprotumumab's approval. While recent advances have expanded the therapeutic landscape, critical gaps persist across access, safety, disease understanding, and treatment optimization — underscoring the breadth of unmet need that continues to drive pipeline activity.

• Treatment access and cost barriers remain substantial: Following teprotumumab's availability, 25.4% of patients recommended for medical therapy did not receive it — 64.3% due to patient refusal (primarily side effect concerns, 88.9%) and 35.7% due to insurance denial. At approximately USD 45,000 per infusion and USD 360,000 for a full eight-infusion course in a 75 kg patient, cost-related access inequity is a persistent structural barrier.

• Ototoxicity and long-term safety concerns require active management: Ototoxicity has emerged as a potentially devastating adverse effect of teprotumumab requiring frequent monitoring, with hearing loss risk higher versus IV or oral glucocorticoids. Long-term safety data remain limited, particularly in women of childbearing age, and free thyroxine levels showed significant decline post-treatment (1.7±1.2 to 1.3±0.4, p=0.049), with over half of patients (52.2%) requiring medication adjustments during therapy for thyroid function.

• Relapse and disease durability represent a critical unmet need: Up to 75% of patients may experience proptosis regression after teprotumumab discontinuation. Active phase patients relapse sooner (mean 8.2 vs. 12.3 months) and experience significantly longer relapse duration (mean 11.1 vs. 4.2 months, p=0.000035) compared to stable phase patients, suggesting teprotumumab functions as a disease modulator rather than a curative agent in active disease.

• A critical treatment timing window narrows the eligible population: Efficacy of both methylprednisolone and teprotumumab is diminished beyond 6 months of TED duration, emphasizing the need for early identification and intervention. This has directed targeting efforts toward patients in the initial active phase (clinical activity score ≥4) within the first 6 months of disease onset.

• The regulatory approval scope of teprotumumab exceeds its evidence base: FDA approval covers TED broadly without distinguishing between active and inactive forms, yet the pivotal trials enrolled only active TED patients (CAS ≥4). Teprotumumab has never been compared head-to-head with other medical therapies in active TED or with surgery in chronic TED, leaving evidence-based treatment selection — balancing benefit/risk ratio, cost/benefit, and long-term outcomes — insufficiently supported.

• Incompletely characterized immune dysregulation limits targeted therapy development: Active-phase thyroid-associated ophthalmopathy (TAO) is marked by significant reductions in regulatory B cells (Bregs) and type 2 conventional dendritic cells, alongside increased type 1 DCs and impaired Breg transition — with reduced suppressive capacity driven by enhanced Breg–DC–monocyte interactions (CD22-PTPRC and BTLA-TNFRSF14). This mechanistic complexity constrains rational drug design.

• Underserved and understudied populations warrant dedicated investigation: Patients with mild-to-moderate TED are being targeted for early low-dose rituximab therapy (100 mg weekly for 4 weeks), with early data showing statistically significant reductions in TRAb levels (p=0.012) and Clinical Activity Score (p=0.027). Regional populations — including the Middle East, UAE, and Gulf region — remain data-scarce, and patients developing TED secondary to monoclonal antibody therapy (e.g., alemtuzumab, nivolumab, immune checkpoint inhibitors) represent a growing, poorly characterized subgroup.

• Next-generation pipeline activity is intensifying in response to teprotumumab's safety profile: Multiple clinical trials are underway evaluating novel agents targeting mTORC1, interleukin-6, FcRn (fragment crystallizable receptor), and IGF-1R. There is broad recognition within academia and industry of the need for agents that are equivalent or superior to teprotumumab in efficacy while offering an improved safety profile — particularly with respect to ototoxicity and long-term systemic effects.

The Durable Efficacy of Lumvoa from the THRIVE Program

Published data on long-term outcomes in thyroid eye disease (TED) reveals a landscape characterized by meaningful short-to-medium-term efficacy across several treatment modalities, but with notable limitations in sustained durability. Intravenous glucocorticoids (IVGCs) remain the most consistently supported first-line therapy, demonstrating reliable control of inflammatory activity — particularly at cumulative doses below 8 g — with favorable tolerability. However, up to 55% of patients show incomplete responses, and recrudescence upon cessation is well-documented. Pulse IVGC therapy yielded a 73.4% responder rate in one cohort, with younger age (mean 52.13 ± 5.18 years vs. 58.80 ± 9.33 years in non-responders, p = 0.02) and lower apparent diffusion coefficient values in the superior and medial rectus muscles identified as predictors of better response. Oral glucocorticoids, by contrast, demonstrated limited and inconsistent benefit, and long-term use carries significant adverse effect burden. For glucocorticoid-resistant disease, tocilizumab has emerged as a clinically meaningful second-line option: across two independent cohorts followed for 24 weeks post-treatment, composite ophthalmic score and GO-QoL primary endpoints were met by 62.5% and 100% of patients, respectively, with CAS reductions of ≥2 points in 75% and 100% of patients. Importantly, no patients experienced TED deterioration during the follow-up window, and the safety profile was acceptable, with only one severe adverse event among 47 total.

Teprotumumab demonstrated the greatest magnitude of benefit across all efficacy domains, but its durability profile is nuanced and disease-phase dependent. In active-phase patients, relapse occurred at a mean of 8.2 months post-treatment, with significantly longer relapse duration (mean 11.1 months vs. 4.2 months in stable-phase patients, p = 0.000035) and potential for clinical progression beyond pretreatment baselines — including at least one case of new-onset optic neuropathy. Stable-phase patients relapsed later (mean 12.3 months), experienced shorter and non-progressive symptom return, and uniformly returned to pretreatment baselines without further deterioration. This pattern suggests teprotumumab functions as a disease modulator in active-phase TED and may trigger a rebound mechanism when initiated during the stable phase. Smoking significantly attenuated outcomes, with smokers demonstrating statistically inferior improvements in diplopia, proptosis, and overall clinical activity scores relative to non-smokers.

Orbital radiotherapy has seen a re-evaluation of its role following earlier skepticism: more recent studies have reconfirmed clinically meaningful benefit in active TED, particularly in steroid-resistant cases. In one cohort, mean Clinical Activity Score fell from 3.309 at baseline to 0.187 at 12 months post-radiotherapy (Cohen's d = 10.88), with disease reactivation occurring in only two patients and minimal adverse events reported across follow-up. Among non-biologic immunosuppressives, mycophenolate mofetil has emerged as the most reliable option, while rituximab has shown moderate efficacy in glucocorticoid-resistant cases. Across the broader literature, most studies remain constrained by follow-up periods of 6 to 24 weeks — and rarely beyond 12 months — leaving the question of true long-term durability incompletely resolved. Surgical intervention for residual manifestations remains frequently necessary following medical therapy, underscoring the ongoing unmet need for treatments with more robust and sustained disease control.

Lumvoa Enters a Dynamic Thyroid Eye Disease Landscape

The treatment landscape for thyroid eye disease (TED) has undergone a fundamental transformation over the past five years, driven primarily by the introduction of targeted biologic therapies. Prior to this shift, management relied heavily on intravenous glucocorticoids (IVGC), with or without orbital radiotherapy, alongside oral glucocorticoids, topical therapies, and, in refractory cases, rituximab or tocilizumab. A 2022 network meta-analysis of 23 studies comprising 1,047 patients confirmed that IVGC combined with orbital radiotherapy ranked first for overall response rates, while IVGC alone remained the most consistently supported first-line option — a position reaffirmed by a 2026 systematic review, which noted favorable tolerability at cumulative doses below 8 g but acknowledged that up to 55% of patients show incomplete responses and that relapses are common. Against this backdrop, teprotumumab — an IGF-1R inhibitor that reduces proinflammatory cytokine production, hyaluronan secretion, and orbital fibroblast activation — emerged as the first FDA-approved biologic for TED, producing statistically significant improvements in proptosis, diplopia, Clinical Activity Score (CAS), and quality of life. The 2024 Bayesian network meta-analysis confirmed teprotumumab's superiority across efficacy domains, with the highest reductions in CAS (MD −1.57, 95% CI −3.81 to 0.68) and proptosis (MD −2.29, 95% CI −2.73 to −1.86), and an overall response rate of RR 5.5 (95% CI 2.3 to 16) versus no treatment.

Real-world data and extension trials have further refined the clinical profile of teprotumumab while also highlighting its limitations. The OPTIC-X open-label extension study demonstrated that 89.2% of patients previously randomized to placebo became proptosis responders upon crossing over to teprotumumab (mean reduction −3.5 ± 1.7 mm), and re-treatment of relapsing responders achieved a 62.5% response rate with a mean proptosis reduction of 1.9 ± 1.2 mm from re-treatment baseline. A 2025 retrospective comparison against intravenous methylprednisolone (IVMP) using the TriNetX platform found no significant difference in the incidence of additional TED-related interventions at 6–18 months post-treatment, though the IVMP cohort exhibited a higher treatment burden among those requiring further intervention (average 2.34 vs. 1.34 additional treatments per patient; 32.8% vs. 5.5% requiring ≥3 treatments). A matched-adjusted indirect comparison confirmed significantly greater quality-of-life gains with teprotumumab versus IVMP across overall, appearance, and visual GO-QoL subscales. However, teprotumumab's widespread adoption is constrained by its safety profile — otic changes (30.3%), weight loss (27.3%), hyperglycemia (18.2%), and over half of patients requiring medication adjustments — as well as its high cost, limited availability outside the United States, and documented racial disparities in prescribing patterns between 2020 and 2023.

Alongside teprotumumab, tocilizumab has consolidated its role as a second-line option for glucocorticoid-resistant TED. A 2026 prospective study across two tertiary centers (Warsaw, Poland; Belgrade, Serbia) in 44 patients receiving tocilizumab 8 mg/kg IV every four weeks for four cycles demonstrated CAS reductions of ≥2 points in 75–100% of patients, proptosis reductions of ≥2 mm in approximately 59% across both cohorts, and a favorable safety profile with only one severe adverse event among 47 total events. A 2024 systematic review of 29 studies further confirmed tocilizumab's efficacy in reducing inflammatory signs during the active phase, with an overall relapse rate of 8.2%. The 2026 systematic review additionally identified mycophenolate mofetil as the most reliable non-biologic immunosuppressive option, and combination regimens — oral mycophenolate with IVGC for proptosis reduction, and oral methotrexate with IVGC for a favorable efficacy-safety balance — as emerging evidence-based strategies. Looking ahead, several novel IGF-1R-targeting agents with alternative administration modalities (VRDN-001 IV; VRDN-002/003 and lonigutamab subcutaneously; linsitinib orally) and neonatal Fc receptor (FcRn) antagonists are under active investigation, signaling continued therapeutic evolution in this space.

Lumvoa's Broad Label Reshapes Thyroid Eye Disease Treatment

The recent FDA approval of Lumvoa for thyroid eye disease (TED) marks a pivotal moment for patients and clinicians navigating this debilitating autoimmune condition. For years, managing TED has been a complex endeavor, often relying on corticosteroids for acute inflammation, which, while effective, carry significant side effects and frequently lead to disease recurrence. Surgical interventions have been the primary recourse for chronic, disfiguring symptoms like proptosis and diplopia that persist after the inflammatory phase.

The arrival of targeted biologic therapies, spearheaded by IGF-1R inhibitors, has revolutionized treatment by addressing the underlying pathophysiology. Lumvoa's distinction lies in its approval for TED regardless of disease activity, a crucial expansion beyond therapies previously limited to the active inflammatory stage. This means a broader spectrum of patients, including those with chronic symptoms who have long awaited a targeted medical option, may now benefit. This expanded indication offers a new pathway for managing the full continuum of TED, potentially reducing the need for invasive surgeries and improving long-term quality of life.

However, this new entrant steps into a market where an established IGF-1R inhibitor has already demonstrated significant efficacy and built considerable physician and patient awareness. While Lumvoa's broader label is a clear differentiator, Viridian will need to navigate the competitive landscape carefully. As an IGF-1R inhibitor, Lumvoa may share some of the known adverse events associated with this class, such as hyperglycemia, hearing impairment, and muscle spasms. Therefore, clinicians will need to remain vigilant, conducting thorough patient screening and ongoing monitoring to balance the profound benefits with these potential risks. The long-term safety profile and real-world effectiveness across diverse patient populations will be critical in shaping Lumvoa's ultimate role in the evolving TED treatment paradigm.